Taro Pharmaceutical Industries Ltd
Change company Symbol lookup
Select an option...
TARO Taro Pharmaceutical Industries Ltd
FREJN Federal Home Loan Mortgage Corp
NXPL NextPlat Corp
CURI CuriosityStream Inc
AXDX Accelerate Diagnostics Inc
MS-I Morgan Stanley
TCRX TScan Therapeutics Inc
TRCK Track Group Inc
NVSGF Nevada Sunrise Metals Corp

Health Care : Pharmaceuticals | Small Cap Value
Based in Israel
Company profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Closing Price
Day's Change
0.42 (1.45%)
B/A Size
Day's High
Day's Low

10-day average volume:

Renault aims for higher profitability this year, though reports a loss for 2022 due to Russia exit

1:38 am ET February 16, 2023 (MarketWatch)

By Joshua Kirby

Renault SA on Thursday said it is aiming to further increase its profitability this year as sales and operating earnings rose in 2022, though the group swung to a net loss as a result of its withdrawal from Russia.

Renault said it will pay a dividend of 25 European cents a share for the year, after two years without.

The French auto maker's operating profit for the year more than doubled on an adjusted basis to 2.22 billion euros ($2.37 billion) on sales that climbed 11% to EUR46.39 billion.

This beat analysts' expectations for sales of EUR45.38 billion, according to a poll compiled by FactSet.

Renault booked an operating margin of 5.6%, rising to 6.4% in the latter half of the year, in line with an ambition to top 5%. The group booked a net loss of EUR338 million after losing EUR1.36 billion in the first half following its decision to unload its Russia business. For continuing operations, Renault made a net profit of EUR1.62 billion.

Looking ahead, Renault said it is aiming for an operating margin of at least 6% in 2023, as well as automotive operational free cash flow of at least EUR2 billion.

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby



(END) Dow Jones Newswires

February 16, 2023 01:38 ET (06:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.